DWP219

DWP219 is a preclinical-stage small molecule analgesic being developed by Daewoong and its subsidiary iN Therapeutics for the management of post-operative pain. It acts as a selective inhibitor of the voltage-gated sodium channel Nav1.8 (Sodium channel protein type 10 subunit alpha), a target located primarily in the peripheral nervous system that is critical for pain signaling. By blocking this specific ion channel, DWP219 aims to offer a non-opioid alternative for acute pain relief, avoiding the risks of addiction and respiratory depression typically associated with narcotics. The drug is part of iN Therapeutics' ion channel-focused pipeline, which utilizes a specialized platform to develop highly selective blockers for sodium channels involved in various pain conditions.